AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05870579
Drug: [68Ga]Ga-NeoB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[68Ga\]Ga-NeoB serves as a radioactive imaging compound to be used for PET imaging for localization of GRPR positive lesions, at screening, potentially at Cycle 2 Day 15 visit, and between 4 and 8 weeks after the last administered dose of \[177Lu\]Lu-NeoB.~\[68Ga\]Ga-NeoB will be administered as a single intravenous (i.v.) dose.
Trial: NCT05870579
Drug: [177Lu]Lu-NeoB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will receive \[177Lu\]Lu-NeoB once every cycle
Trial: NCT05369390
Drug: NNC0487-0111 A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive NNC0487-0111 A tablet once daily.
Trial: NCT05369390
Drug: NNC0487-0111 B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive NNC0487-0111 B tablet once daily.
Trial: NCT06355349
Drug: Reference Drug or Test Drug
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, Oral, QD for 1 Day, Washout period is more than 21 days after administration
Trial: NCT04323475
Drug: Xeroform
RxNorm normalized name: DRESSING,XEROFORM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care will consist of Xeroform primary dressing and Kenacomb topical antibiotic cream (for wounds with signs of localized infection)
Trial: NCT05145660
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent cisplatin (100 mg/m², d1-3, Q3w, maximum to three cycles); The application of induction chemotherapy and consolidation chemotherapy is dependent on the physician's discretion.
Trial: NCT05850494
Drug: HFA MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Dose formulation: MDI~* Unit dose strength(s): Reference (propellant only)~* Dosage Level: 4 inhalations, single dose~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 or 2 possible sequences AB or BA
Trial: NCT04739371
Drug: Insulin, Regular, Human
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The spray will last a few seconds and then the participant will be asked to sniff to aid the drug into the nose. The device (i.e. ViaNase) is an atomizer that uses its patented technology that turns the liquid into a fine mist of droplets to facilitate the drug along the nose to brain pathway. Each nostril will receive this administration 2 times for a total of 40 IUs or 0.4 mL of liquid.
Trial: NCT04739371
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The spray will last a few seconds and then the participant will be asked to sniff to aid the saline into the nose. The device (i.e. ViaNase) is an atomizer that uses its patented technology that turns the liquid into a fine mist of droplets to facilitate the drug along the nose to brain pathway. Each nostril will receive this administration 2 times for a total of 40 IUs or 0.4 mL of liquid.
Trial: NCT06239623
Drug: JSI-1187
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use ERK inhibitor JSI-1187 to treat solid tumor
Trial: NCT05201794
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for each dose level as tablet will be administered orally.
Trial: NCT05945147
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An escalating dose of normal saline (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
Trial: NCT06564467
Drug: JMT202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT06564467
Drug: Placrbo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT05669924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for methylphenidate
Trial: NCT04944862
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered intravenously
Trial: NCT06567522
Drug: Lumbar Erector Spinae Plane Block. L bupivacaína 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided ESP-L shall be carried out at the L3-14 level with 30 mL of levobupivacaine 0.25%
Trial: NCT05245448
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05703672
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One pill (white) once daily for days 1-3, one pill (white) twice daily for days 4-7 and one pill (blue) twice daily from day 8 through week 12.
Trial: NCT05389423
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/m2/day administered by CIVI on days 1 to 4
Trial: NCT05389423
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 administered IV on day 5
Trial: NCT05775536
Drug: Aspirin 500Mg Tab
RxNorm normalized name: ASPIRIN 500MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 1 tablet per day starting from visit 2 until visit 3, intake in the evening
Trial: NCT05874921
Drug: Jelmyto (mitomycin) for pyelocalyceal solution
RxNorm normalized name: Jelmyto Pyelocalyceal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of Jelmyto to be instilled is 4 mg per mL via ureteral catheter or a nephrostomy tube, with total instillation volume based on volumetric measurements using pyelography, not to exceed 15 mL (60 mg of mitomycin).~Instill Jelmyto once weekly for six weeks. For patients with a complete response 3 months after Jelmyto initiation, Jelmyto instillations may be administered once a month for a maximum of 11 additional instillations.
Trial: NCT06061848
Drug: ILIT + placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of Sodium chloride solution 9 mg/mL as intramuscular injection followed by 0,1 mL of Alutard SQ timothy, ALK Nordic, 10 000 SQ-U/mL as three intralymphatic injections
Trial: NCT05102409
Drug: Xiidra® (5% lifitegrast ophthalmic solution)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiidra® (5% lifitegrast ophthalmic solution) dosed once
Trial: NCT06430307
Drug: Saussurea Involucrata Liquid Tonic
RxNorm normalized name: Saussurea involucrata whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This product is a single preparation of Saussurea Involucrata Liquid Tonic. It is used for rheumatoid arthritis, rheumatoid arthritis and dysmenorrhea caused by insufficient kidney yang and cold-damp stasis.
Trial: NCT04903821
Drug: BAY3427080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered, single dose on Day 1 and single does once daily on Day 3 to 8
Trial: NCT05346445
Drug: Fluoxetine 20 MG
RxNorm normalized name: fluoxetine 20 MG
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received non-hormonal treatment with fluoxetine.
Trial: NCT06701110
Drug: [U-14C] WX-081
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of approximately 450 mg (100 μCi) of \[U-14C\] WX-081 will be administered to healthy male volunteers. The study will involve pharmacokinetic assessments, including metabolism, mass balance, and excretion pathways, through the collection of biological samples such as blood, plasma, urine, and feces.
Trial: NCT06537908
Drug: Anti-PD-1/PD-L1 antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1/PD-L1 Intravenous injection for at least 6 months
Trial: NCT06137365
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gummy product will be prepared using the same ingredients as the cannabis gummy but will not contain active cannabinoids.
Trial: NCT05505994
Drug: DWP16001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP16001 A mg tablet
Trial: NCT05505994
Drug: DWP16001 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP16001 Placebo tablet
Trial: NCT05687916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-861 placebo matching tablets.
Trial: NCT06004401
Drug: Rabeprazole +colloidal pectin bismuth +Amoxicillin +Clarithromycin
RxNorm normalized name: bismuth / pectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole tablets 10mg 2/day+colloidal pectin bismuth 200mg 2/day+Amoxicillin 1g 2/day+Clarithromycin 500mg 2/day
Trial: NCT06004401
Drug: Vonopazan +Minocycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonopazan 20mg 2/day+Minocycline 100mg 2/day
Trial: NCT06004401
Drug: Rabeprazole +colloidal pectin bismuth +Metronidazole +Clarithromycin
RxNorm normalized name: bismuth / pectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole tablets 10mg 2/day+colloidal pectin bismuth 200mg 2/day+Metronidazole 0.4g 3/day+Clarithromycin 500mg 2/day
Trial: NCT04957914
Drug: LY3209590
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00864409
Drug: saline.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wound infiltration with 170 mL sterile saline
Trial: NCT05356728
Drug: Thealoz Duo (combination of trehalose and hyaluronate) eye drop and Hyabak (hyaluronate) eye drop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One of the eyes will be assigned to use Thealoz Duo while the other with Hyabak by using randomisation table
Trial: NCT05805683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients in this group will receive 1 ml of saline placebo solution subcutaneously per day for 2 weeks starting within 48 hours after injury.
Trial: NCT05038410
Drug: Wobenzym®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wobenzym®
Trial: NCT06003179
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conditioning chemo at different doses
Trial: NCT05244642
Drug: Investigator's choice of Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive one of the following chemotherapies, including but not limited to DHAP (cisplatin 100mg/m2 D1, high dose cytarabine 2 mg/m2 q12h D2, dexamethasone 40mg D1-4, Q3W); ESHAP (etoposide 40 mg/m2 D1-4, cisplatin 25 mg/m2 D1-4, high dose cytarabine 2 mg/m2 D5, methylprednisolone 500mg D1-4, Q3W); DICE (dexamethasone 10mg/m2 D1-4, ifosfamide 1.0g/m2 D1-4, cisplatin 25mg/m2 D1-4, etoposide 60 mg/m2 D1-4, Q3W); ICE (ifosfamide 5 mg/m2 D2, carboplatin AUC 5 D2, etoposide 100 mg/m2 D1-3, Q3W); IGEV (ifosfamide 2 mg/m2 D1-4, gemcitabine 800 mg/m2 D1, D4, vinorelbine 20mg/m2 D1, prednisone 100 mg D1-4, Q3W); GVD (gemcitabine 1g/m2 D1, D8, vinorelbine 20 mg/m2 D1, D8, liposome doxorubicin 15 mg/m2 D1, D8, Q3W); MINE (etoposide 65mg/m2 D1-3, ifosfamide 1.33g/m2 D1-3, mitoxantrone 8mg/m2 d1, Q3W); GemOx (gemcitabine 800mg/m2 D1, D8, oxaliplatin 85mg/m2 D1, Q3W); GemOx (gemcitabine 1000mg/m2 D1, oxaliplatin 100mg/m2d1, Q2W).
Trial: NCT05851976
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 500mg twice daily for 16 days
Trial: NCT04822584
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once a day orally for 36 weeks
Trial: NCT04461041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet manufactured to mimic empagliflozin 10 mg tablet
Trial: NCT06397781
Drug: Skin Cleanser Combination No.1
RxNorm normalized name: skin cleanser combination no.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Mupirocin 2% nasal ointment to the anterior nares to be applied twice daily~2. Chlorhexidine 4% topical soap (Hibiclens) to be used every other day in the shower or bath from the neck down and then completely rinsed.~3. Sulfamethoxazole/trimethoprim (Bactrim): one double strength (DS) tablet (800 mg/160 mg) twice per day for adolescents and adults. Dosing for pediatric patients will be calculated to 5 to 6 mg/kg trimethoprim also given twice daily.
Trial: NCT06088732
Drug: Ibuprofen 800 mg
RxNorm normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single oral dose of Ibuprofen
Trial: NCT06088732
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT05051930
Drug: TQC3721 suspension for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 0.2 mg/1.0 mg/3.0 mg/6.0 mg/12.0 mg/24.0 mg single dose of TQC3721 suspension for inhalation.
Trial: NCT05051930
Drug: TQC3721 suspension placebo for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 0mg single dose of TQC3721 suspension placebo for inhalation .
Trial: NCT04839575
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally (daily)
Trial: NCT04647487
Drug: LY3484356
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05911282
Drug: N Acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study began at 7 pm, when the volunteers in NAC group drank the contents of a numbered cup with NAC (1.2 g of NAC). At 9 pm, they were given the second cup with 1.2 g of NAC corresponding to their randomized number.~The cups with pure substance NAC were prepared and numbered by the physician not attending the drinking just before the study.
Trial: NCT06002789
Drug: MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For MSI-H/MSS (dMMR/pMMR) mixed sMPCC, a combination of neoadjuvant chemotherapy with mFOLFOX6 and immunotherapy with PD-1 monoclonal antibody are applied.
Trial: NCT06002789
Drug: All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For all-MSI-H (dMMR) sMPCC, single-drug PD-1 monoclonal antibody immunotherapy is applied.
Trial: NCT04998201
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile Normal Saline (0.9% NaCl)
Trial: NCT06406829
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the placebo group, the 0.9% saline is administered with the same volume at the same speed as the dexmedetomidine group
Trial: NCT06209385
Drug: YZJ-5053 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YZJ-5053 tablets will be administrated orally QD for 21 days
Trial: NCT06430827
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine (1000 mg/m\^2) will be administered orally in a 2-week treatment cycle, twice a day from day 1 to day 10 of each cycle
Trial: NCT06610279
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-951 matching placebo SC injection
Trial: NCT05273749
Drug: TNX-102 SL Tablet, 5.6 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Trial: NCT05273749
Drug: Placebo SL Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Trial: NCT06325930
Drug: [14C]-HU6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]-HU6 following a single dose of HU6 in healthy, adult male subjects
Trial: NCT06154447
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension for Oral Administration
Trial: NCT06154447
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension and Tablets for Oral Administration
Trial: NCT04647890
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo capsules once daily for 12 weeks
Trial: NCT05567094
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 2ml saline placebo, administered as an intravenous bolus within 5 minutes after induction of anesthesia
Trial: NCT06392321
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: comparison between bupivacaine, bupivacaine and fentanyl.
Trial: NCT06702943
Drug: Tigecycline (Tygacil)
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tigecycline-based regimen administered both intravenously (IV) and intraventricularly (IVT) for 14-21 days
Trial: NCT06519266
Drug: IPI1/NIVO3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with 2 cycles of i.v. ipilimumab 1mg/kg and nivolumab 3mg/kg q3w, followed by continued i.v. nivolumab 480mg q4w up to 1 year.
Trial: NCT06519266
Drug: IPI3/NIVO1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with 4 cycles of intravenous (i.v.) infusion with ipilimumab 3mg/kg and nivolumab 1mg/kg q3w followed by continued i.v. nivolumab 480mg q4w up to 1 year.
Trial: NCT05146219
Drug: TY-9591 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TY-9591 Tablets 160mg/d
Trial: NCT02179138
Drug: TFV 1% gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05876858
Drug: 11C-butanol
RxNorm normalized name: BUTANOLS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to four weeks depending on subject, imaging agent and scanner availability. Subjects will be asked to complete the HEAL questionnaires before or after their PET/CT scan on each day.
Trial: NCT04906473
Drug: KY100001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KY100001; Tablet; Oral route; Dose escalation and dose extension
Trial: NCT05262556
Drug: NP-101 (TQ Formula)
RxNorm normalized name: NP Thyroid Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, five 600mg tabs daily every three weeks for four cycles (21-day cycle), then maintenance for an additional 12 weeks for a total of six cycles.
Trial: NCT05080790
Drug: Dinutuximab Beta, Zoledronic acid, Interleukin-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five 5-week cycles (Q5W) of dinutuximab beta, zoledronic acid and low-dose interleukin (IL-2)
Trial: NCT04827875
Drug: AIV001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal
Trial: NCT06625177
Drug: TEV-53408
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEV-53408 injection administered subcutaneously
Trial: NCT05768139
Drug: STX-478
RxNorm normalized name: STX-478
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STX-478 is a mutant-selective PI3Kα inhibitor
Trial: NCT05236387
Drug: 99m Tc-TM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will receive a single injection (0.1 ml) of 99mTc-TM (50 mcg) at the upper outer skin of the breast using an intradermal technique confirmed by the presence of a skin wheal.
Trial: NCT06637631
Drug: SAR441566 matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablet Route of administration: Oral
Trial: NCT05761015
Drug: therapeutic program including intermittent drug intake and multimodal rehabilitation program
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The prescribed NSAID molecule shall be chosen according to the patient's risk profile:~* gastric/duodenal risk: age \>65, history of ulcer with remission, history of inflammatory event, current low-dose acetylsalicylic acid treatment ;~* cardiovascular risk (according to Agostino scale \& SCORE);~The molecule with therefore be:~* no risk: niflumic acid, 250 mg per intake;~* gastric/duodenal risk only: diclofenac, 50-100 mg per intake, plus lansoprazole;~* cardiovascular risk only: ketoprofen, 50-100 mg per intake;~* double risk: ibuprofen, 200-400 mg per intake, plus lansoprazole. For the walk test, the highest dose of diclofenac or ketoprofen will be used. Then, the patient will be free to half the dose if pain relief is achieved so.~One gram of acetaminophen will be added to any NSAID intake. The number of intakes will be limited to twice a day (morning and evening) and to 10 times a week.
Trial: NCT04804514
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is applied to teeth
Trial: NCT06636734
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05384197
Drug: Enhanced regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 2 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (2 days with the last day of AP course being one day prior to intervention)